Impact of carboxylesterase 1 genetic polymorphism on trandolapril activation in human liver and the pharmacokinetics and pharmacodynamics in healthy volunteers
Abstract Trandolapril, an angiotensin‐converting enzyme inhibitor prodrug, needs to be activated by carboxylesterase 1 (CES1) in the liver to exert its intended therapeutic effect. A previous in vitro study demonstrated that the CES1 genetic variant G143E (rs71647871) abolished CES1‐mediated trandol...
Saved in:
Main Authors: | Xinwen Wang (Author), Lucy Her (Author), Jingcheng Xiao (Author), Jian Shi (Author), Audrey H. Wu (Author), Barry E. Bleske (Author), Hao‐Jie Zhu (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2021-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Impact of genetic polymorphisms on the pharmacokinetics and pharmacodynamics of lenvatinib in patients with hepatocellular carcinoma
by: Hironao Okubo, et al.
Published: (2022) -
Study of GABA in healthy volunteers: pharmacokinetics and pharmacodynamics
by: Junfeng eLi, et al.
Published: (2015) -
The effects of rabeprazole on metformin pharmacokinetics and pharmacodynamics in Chinese healthy volunteers
by: Guojing Liu, et al.
Published: (2016) -
Genetic Polymorphisms Associated With the Pharmacokinetics, Pharmacodynamics and Adverse Effects of Olanzapine, Aripiprazole and Risperidone
by: Paula Soria-Chacartegui, et al.
Published: (2021) -
Oxypurinol pharmacokinetics and pharmacodynamics in healthy volunteers: Influence of BCRP Q141K polymorphism and patient characteristics
by: Bianca Vora, et al.
Published: (2021)